The Queen Square Radiosurgery Centre –  treating brain tumours and disorders

The Queen Square Radiosurgery Centre provides a Gamma Knife radiosurgery service for NHS and private patients treating brain tumours and other intracranial indications. The Gamma Knife is not a knife at all, but a highly sophisticated, non-invasive device that focuses high-energy gamma radiation on the affected area inside the brain. Gamma Knife radiosurgery is an effective, non-invasive alternative to traditional surgery.

We are one of two NHS England National Centres of Excellence who provide specialist care and support for patients including those with rare and complex conditions. The centre enjoys a significant number of strengths from the well established integration with other areas of expertise within the University College London Hospitals NHS Foundation Trust (UCLH) and is located at The National Hospital for Neurology and Neurosurgery, the UK’s largest dedicated neurological and neurosurgical hospital.

Gamma Knife can treat

General enquiries

+44 (0) 20 3448 4077

Patient FAQs

Find out what Gamma Knife radiosurgery is, how it works and its advantages amongst other things we are frequently asked.
View FAQs

Latest News

Clinical team represented at European Leskell Gamma Knife Society meeting

The clinical team at QSRC was represented at the European Leskell Gamma Knife Society meeting held in Rome, Italy (17-19 November) by Consultant...

2000th patient treated at our sister site – the Thornbury Radiosurgery Centre

Earlier in November, the 2000th patient was treated at The Thornbury Gamma Knife Centre  since its opening in 2008. Staff at the centre presented...

Conference news

The 14th congress of the International Stereotactic Radiosurgery Society (ISRS) will be held in Rio de Janeiro, Brazil between the 9th-13th June...

Update on large multi-institutional study on radiosurgery for multiple metastases published

There is now an update on the large prospective study on radiosurgery for multiple metastases that was published by Lancet Oncology in 2014....